Liver transplantation for unresectable neuroendocrine tumor liver metastases

Annals of Surgical Oncology

Volumn 21, Issue 7, 2014, Pages 2398-2405

  Rossi, Roberta Elisa ^a,b   Burroughs, Andrew Kenneth ^c   Caplin, Martyn Evan ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A;

ARTICLE; ARTIFICIAL EMBOLISM; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FOLLOW UP; HEPATOMEGALY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); METASTATIC COLORECTAL CANCER; MULTICENTER STUDY (TOPIC); NEUROENDOCRINE TUMOR; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; RISK FACTOR; SURVIVAL RATE; TUMOR DIFFERENTIATION; CLINICAL TRIAL (TOPIC); LIVER NEOPLASMS; MORTALITY; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PATHOLOGY; PROGNOSIS; SECONDARY;

CLINICAL TRIALS AS TOPIC; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; NEUROENDOCRINE TUMORS; PROGNOSIS; SURVIVAL RATE;

EID: 84902165931     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3523-y     Document Type: Article

References (46)

1. Warner R. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology. 2005;128:1668-84.
2. Modlin IM, Oberg K, Chung DC, RT Jensen, WW de Herder, RV Thakker, et al. Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol. 2008;9:61-72.
3. Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, (eds). WHO classification of tumors of the digestive system. Lyon: International Agency for Research on Cancer (IRAC); 2010. p. 13-14.
4. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157-76.
5. Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083-92.
6. Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? J Hepatol. 2007;47:460-6.
7. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677-82.
8. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37.
9. Bacchetti S, Bertozzi S, Londero AP, Uzzau A, Pasqual EM. Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors: a meta-analysis of observational studies. Int J Hepatol. 2013;2013:235040.
10. Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malignancy: indications, limitations, and analysis of the current literature. Liver Transpl. 2010;16:930-42.
11. Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al; UK and Ireland Neuroendocrine Tumor Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors (NETs). Gut. 2012;61:6-32.
12. Honore C, Detry O, De Roover A, Meurisse M, Honore P. Liver transplantation for metastatic colon adenocarcinoma: report of a case with 10 years of follow-up without recurrence. Transpl Int. 2003;16:692-3.
13. Urata K, Kawasaki S. Liver transplantation for liver metastases of colorectal cancer [in Japanese]. Nippon Geka Gakkai Zasshi. 2001;102:409-11.
14. Le Treut YP, Delpero JR, Dousset B, Cherqui D, Segol P, Mantion G, et al. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg. 1997;225:355.
15. Lehnert T. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation. 1998;66:1307-12.
16. Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, et al. Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation. 2002;73:386-94.
17. Ahlman H, Friman S, Cahlin C, Nilsson O, Jansson S, Wangberg B, et al. Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014:265-9.
18. Florman S, Toure B, Kim L, Gondolesi G, Roayaie S, Krieger N, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004;8:208-12.
19. Frilling A, Malago M, Weber F, Paul A, Nadalin S, Sotiropoulos GC, et al. Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl. 2006;12:1089-96.
20. Van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: defining selection criteria to improve survival. Liver Transpl. 2006;12:448-56.
21. Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, et al. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. Liver Transpl. 2007;13:327-33.
22. Le Treut YP, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, et al. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. Am J Transplant. 2008;8:1205-13.
23. Sher L. Association between timing of resection of primary tumor in patients undergoing liver transplantation for metastatic neuroendocrine tumor and survival. Am J Transplant. 2009;12:88.
24. Bonnacorsi-Riani E, Apestegui C, Jouret-Mourin A, Sempoux C, Goffette P, Ciccarelli O, et al. Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. Transplant Int. 2010;23:668-78.
25. Gedaly R, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg. 2011;146:953-8.
26. Máthé Z, Tagkalos E, Paul A, Molmenti EP, Kóbori L, Fouzas I, et al. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. Transplantation. 2011;91:575-82.
27. N'Guyen NT, Harring TR, Goss JA, O'Mahony C. Neuroendocrine liver metastases and orthotopic liver transplantation: the US experience. Int J Hepatol. 2011:742890.
28. Le Treut YP, Grégoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J, et al; for ELITA. Liver transplantation for neuroendocrine tumors in Europe - results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg. 2013;257:807-15.
29. Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol. 2005;16:1806-10.
30. Clavien PA, Lesurtel M, Bossuyt PMM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012;13:E11.
31. Kornberg A, Kupper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol. 2010;36:275.
32. Aberg F, Pukkala E, Hockerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl. 2008;14:1428-36.
33. Jain A, Patil VP, Fung J. Incidence of de novo cancer and lymphoproliferative disorders after liver transplantation in relation to age and duration of follow-up. Liver Transpl. 2008;14:1406-11.
34. Maggi U, Consonni D, Manini MA, Gatti S, Cuccaro F, Donato F, et al. Early and late de novo tumors after liver transplantation in adults: the late onset of bladder tumors in men. PLoS One. 2013;8:e65238.
35. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006;4:CD005161.
36. Vivarelli M, Cucchetti A, La Barba G, Ravaioli M, Del Gaudio M, Lauro A, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248:857.
37. Rodríguez-Perálvarez M, Tsochatzis E, Naveas MC, Pieri G, García-Caparrós C, O'Beirne J, et al. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. J Hepatol. In press.
38. Cheng JW, Shi YH, Fan J, Huang XW, Qiu SJ, Xiao YS, et al. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2011;137:1445.
39. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001;7:811-5.
40. Kashyap R, Jain A, Reyes J, Demetris AJ, Elmagd KA, Dodson SF, et al. Causes of death after liver transplantation in 4000 consecutive patients:2 to 19 year follow-up. Transplant Proc. 2001;33:1482-3.
41. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant. 2010;10:1420-7.
42. Schoening WN, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, et al. Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases. Am J Transplant. 2013;13:2384-94.
43. Mazzaferro V. Surgical approach to the treatment of liver metastases from neuroendocrine tumors: hepatic resection and liver transplantation. Tumori. 2010;96:833-46.
44. Pascher A, Klupp J, Neuhaus P. Endocrine tumors of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumors. Best Pract Res Clin Gastroenterol. 2005;19:637-48.
45. Grégoire E, Le Treut YP. Liver transplantation for primary and secondary endocrine tumors. Transplant Int. 2010;23:704-11.
46. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumors in relation to the extent of hepatic disease. Br J Surg. 2009;96:175-84.